The European Antitrust Agenda: Remedies Off the Table in MMG/Anglo American; Digital Markets Rules Event to Highlight Latest Clashes Over Rollout

Welcome to The European Antitrust Agenda, our weekly overview of European tech and competition law developments. Key stories we’re following this week include: • Remedies no longer an option in MMG/Anglo American nickel deal • Our conference on the EU’s digital markets rules sets the stage for latest tensions • What else is happening

EU Big Tech Case Tracker

This is The Capitol Forum’s Big Tech tracker, where we follow investigations and other proceedings targeting technology giants like Apple (AAPL), Alphabet (GOOG), Meta (META) and more across the...

Sep 22, 2026 Read Now >

Antitrust Agenda: Minnesota AG Announces Investigation into Fertilizer Industry; Adam Candeub’s Written Responses to Judiciary Committee Questions; Institutional Investor Common Ownership of Competitors is a Plus Factor, District Court Finds; Colorado AG Phil Weiser on Opportunities for State AGs Next Congress

Welcome to The Antitrust Agenda, our weekly analysis of timing and priorities at the FTC, DOJ, and state AG offices. Key stories we’re following this week include: • Minnesota Attorney General...

Sep 21, 2026 Read Now >

Paramount/Warner Bros. Discovery: Negotiators in Settlement Discussions Reach Advanced Stage Navigating Between Contrasting Economic Goals

Paramount Skydance (PSKY) and the California attorney general’s discussions to settle a suit to block the studio’s proposed Warner Bros. Discovery (WBD) acquisition have reached an advanced stage...

Sep 19, 2026 Read Now >

The European Antitrust Agenda: Remedies Off the Table in MMG/Anglo American; Digital Markets Rules Event to Highlight Latest Clashes Over Rollout

RELATED ARTICLES | Antitrust Policy

EU Big Tech Case Tracker

Paramount/Warner Bros. Discovery: Negotiators in Settlement Discussions Reach Advanced Stage Navigating Between Contrasting Economic Goals

FILTER BY

This article is currently locked and only available to subscribers. Request a trial to receive unlimited access to all articles.